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Human N-acetylation genotype
determination with urinary
caffeine metabolites
The human acetylation genotype was determined by measuring urinary caffeine metabolites by use of a
modification of a previously published HPLC method. The problem of separation of 7-methylxanthine
(7X) from 1-methyluric acid (1U) in urine extracts was achieved by adding a phenyl column, in tandem
with a C18 reverse-phase column, by means of a methanol: aqueous acetic acid gradient elution system.
The urinary molar ratios of (AANIU)/ (AAA/1U + 1U + 1X) and (AAA/1U) / (1X) were estimated in 20
subjects phenotyped with dapsone, with 100% concordance for the [AAA/UNIX] ratio. A population
study of 42 unrelated individuals exhibited trimodal distribution in acetylation capacity, consistent with
the Hardy-Weinberg theory of population genetics. Defmitive pedigree analysis of 16 families (75 subjects)
resulted in significant similarity between the observed genotypic matings and those expected by classical
Mendelian segregation. This noninvasive genotyping method promises to be useful in future investigation
of the relationship between the human acetylation polymorphism and clinical disorders. (CLIN
PHARMACOL THER 1990;47:470-7.)
Anthony J. Kilbane, MB, BCh,a Lawrence K. Silbart, PhD,b Melanie Manis, PhD,c
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Techniques employed in N-acetylation phenotyping
have, traditionally, required the subjects tested to con-
sume predetermined doses of such drugs as isoniazid,1.2
sulfamethazine,3 sulfasalazine dapsone,5,6 and pro-
cainamide.' Multiple dose administrations, complex ex-
traction processes, ethical constraints, reluctance by
some to ingest these agents and hypersensitivity reac-
tions in predisposed individuals were major disadvan-
tages encountered when population studies were un-
dertaken for more extensive assessment of the relation-
ship between acetylator status and clinical disease."
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Recent experience with caffeine as a test drug for
determination of the human acetylator phenotype might
circumvent some of the problems mentioned above,
inasmuch as this universally available substance is
consumed on a daily basis by a substantial number of
people.
The isolation' and identification by HPLC" of a
urinary caffeine metabolite, 5-acetylamino-6-amino-3-
methyluracil (AAMU), and an additional unidentified
acetylated metabolite, excreted in urine in varying con-
centrations depending on the acetylator phenotype,14
led to further evaluation of caffeine as a suitable
substrate for investigation of the human acetylation
polymorphism. This latter compound, identified as 5-
acetylamino-6-formylamino-3-methyluracil (AFMU),
was proved to be a major uracilic metabolite of caf-
feine.1516 Urinary concentration of AFMU was directly
related to N-acetyltransferase enzyme activity'' and
formed the basis for determination of the acetylator
phenotype by use of the urinary molar ratio of AFMU
to 1-methylxanthine (1X).18 Instability of AFMU and
its spontaneous conversion to AAMU by deformylation
with dilute sodium hydroxide led to quantitation of
the urinary molar ratio of (AAMU)/ (1X) to deter-
mine the acetylator phenotype. 19 AAMU was found
to be more stable than its biologic precursor. In
an attempt to separate homozygous from heterozy-
gous rapid acetylators, the urinary molar ratio of
(AAMU)/ (AAMU + 1U + IX) was measured in a
selected population and reflected a trimodal distribution
in N-acetylation patterns.'
The purpose of the present study is, through stud-
ies of a random population combined with family
pedigree analysis, to further investigate the urinary
molar ratio of AAMU to products (1U and 1X) of
the 7-demethylation pathway of paraxanthine (1,7-
dimethylxanthine) metabolism, for future application
as an acetylator genotyping method.
METHODS
Subjects. After receiving approval from the Human
Resources Committee of the University of Michigan
(Ann Arbor, Mich.), subjects in the study were re-
quested to avoid food and beverages that contained
methylxanthines for 48 hours or longer. Subjects then
consumed a caffeine-containing drink, (e.g., coffee or
cola) and supplied a urine sample 6 hours later. After
adjustment of each urine sample to pH 3.5 with 6N
hydrochloride, a 10 ml aliquot was stored at 20° C
until assayed. Excluded from the study were individuals
with idiosyncratic reactions (e.g., tachycardia, tremors,
and insomnia) to caffeine. No other specific dietary
restrictions were enforced. Three groups of individuals
were then analyzed as follows: (1) Twenty healthy sub-
jects, previously phenotyped with dapsone by use of
the method of Can et al.,' were selected and retested
by use of the caffeine method; (2) a population study
of 42 unrelated adult white persons from the local com-
munity was undertaken to estimate the gene frequency
and to further evaluate the expected trimodal distribu-
tion pattern; and (3) informative family studies of pa-
tients with type I (insulin-dependent) diabetes mellitus,
attending the pediatric endocrinology clinics at the Uni-
versity of Michigan hospitals, and their first-degree rel-
atives, in addition to families living in the locality, were
tested for acetylation capacity. A detailed pedigree anal-
ysis, consisting of 16 families (75 subjects), was un-
dertaken to assess the Mendelian segregation patterns.
Material. Caffeine, 1-methyluric acid (1U), 1-
methylxanthine ( I X), N-acetyl-p-amidophenol , ben-
zyloxyurea, and 7-methylxanthine (7X) were obtained
from Sigma Chemical Co. (St. Louis, Mo.) at the high-
est purity available. AFMU was supplied by Dr. W.
Kalow (University of Toronto, Toronto, Ontario, Can-
ada). All HPLC buffers were spectroscopic grade.
AAMU was prepared by deformylation of AFMU with
dilute sodium hydroxide.
Analytic procedures. Because of incomplete reso-
lution of AFMU from interfering peaks in the early
phase of the chromatogram with the C18 octyldecylsilane
reverse-phase column, urinary AAMU concentration
A
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Fig. 1. HPLC chromatograms of solvent extracted urine from
two individuals, A and B, by use of the Cis reverse-phase
5 im column and conditions described by Grant et al.'' Ex-
tracted urine from subject A shows satisfactory resolution of
1U but that from subject B is an example of incomplete
separation of 1U from 7X. Conditions: isocratic elution with
0.05% aqueous acetic acid/methanol (88:12, vol/ vol) at a
flow rate of 1.2 ml per minute and ultraviolet absorbance at
280 nm. Retention times: 7-methylxanthine (X), 6.6 minutes;
1-methyluric acid (1), 6.8 minutes; 1-methylxanthine (2), 9.3
minutes; internal standard (IS), N-acetyl-p-amidophenol, 10.2
minutes.
was measured by the HPLC method of Tang et al.'
The stored urine samples were thawed and a 50 p.1
aliquot was withdrawn and treated with 50 p.1 of 0.2N
sodium hydroxide for 10 minutes at room temperature
to achieve a final pH greater than 8, for quantitative
deformylation of AFMU to AAMU. Then 50 pd of 0.2
mol/ L hydrochloride was added to neutralize excess
base and 100 pi of the internal standard, benzyloxyurea
(1 mg/ ml in 0.1% aqueous acetic acid) was added,
from which a 20 p.1 sample was injected onto a Bio-
Gel TSK-20 (300 x 7.5 mm) size exclusion HPLC
column (Richmond, Calif.). A Varian 5060 program-
mable HPLC solvent delivery system (Walnut Creek,
Calif.) with a Rheodyne injector (Cotati, Calif.), Varian
ultraviolet-100 detector, and a Spectrophysics SP4270
integrator (San Jose, Calif.) were used to perform the
separation and quantitation. An isocratic elution with
0.1% aqueous acetic acid at 0.8 ml per minute flow
rate was maintained, and the column eluent ultraviolet
absorption was monitored at 254 nm. The identical
protocol was performed with baseline urine samples that
were spiked with known amounts of AAMU standards.
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Fig. 2. HPLC chromatogram of solvent-extracted urine from
an individual after a 48-hour abstinence from methylxanthine-
containing food and drink (upper tracing), and urine from
the same individual 6 hours after caffeine ingestion (lower
tracing). The aliquot of urine extract was injected onto
a phenyl column in tandem with a Cis reverse-phase col-
umn. A gradient elution was performed as shown (broken
line). Aqueous phase: 0.05% aqueous acetic acid/ water; or-
ganic phase: methanol. Retention times: 1-methyluric acid
(1), 14.6 minutes; 7-methylxanthine (2), 15.2 minutes; 1-
methylxanthine (3) 17.7 minutes; internal standard (IS), N-
acetyl-p-amidophenol, 18.7 minutes.
Standard curves relating the integrated signal values
(relative to the internal standard, benzyloxyurea) versus
known amounts of AAMU standards, processed as
above, were constructed. Subsequent urinary AAMU
concentrations were calculated by interpolation from
the linear standard curve.
By use of a C/8 reverse-phase column under the
HPLC conditions reported by Grant et al.," difficulties
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in the separation of 1U from 7X were encountered in
at least one third of the urine samples tested (Fig. 1),
which persisted despite manipulation of the gradient
conditions.
For quantitation of 1U and 1X, a modification of the
method of Grant et al." was used. To a 200 p.1 urine
sample was added 120 mg ammonium sulfate, and the
sample was then vortexed briefly in a 15 ml Corex
(Corning, Corning, N.Y.) tube. A 200 p.1 aliquot of
the internal standard, N-acetyl-p-amidophenol (100
mg/L in chloroform) was added, followed by the ad-
dition of 6 ml chloroform: isopropanol (85 :15) and the
mixture was vortexed for 30 seconds. After centrifu-
gation at 2,500g for 5 minutes at room temperature,
the aqueous phase was removed and discarded, and the
organic phase was evaporated to dryness with a gentle
stream of nitrogen at 45°C. The residue was redissolved
in 800 RI methanol/ 0.05% aqueous acetic acid-water
(12:88, vol/vol). A 20 R.1 aliquot was then injected
onto a Waters RBondapak phenyl column (3.9 x
150 mm; Waters Associates, Milford, Mass.) in
tandem with a Beckman Ultrasphere octyldecylsilane
column (5 p.m. 250 x 4.6 mm; Beckman Instruments,
Palo Alto, Calif.) to separate 1U from 7X. Separation
was consistently accomplished by use of the gradient
elution profile shown in Fig. 2. The addition of a
phenyl column improved the resolution of these me-
tabolites, allowing satisfactory quantitation of both 1U
and 7X on all samples tested. It was not unusual for
the integrated 7X signal to exceed that of 1U, and
attempts to separate these metabolites by use of a
phenyl column alone were unsuccessful. The identical
protocol was performed with baseline urine samples that
were spiked with known amounts of 1X and 1U stan-
dards, and the ultraviolet absorbance was monitored at
272 nm. Standard curves relating the integrated signal
values (relative to the internal standard, N-acetyl-p-
amidophenol) versus known amounts of 1X and 1U
standards, processed as above, were constructed. Sub-
sequent urinary IX and 1U concentrations were cal-
culated by interpolation from the linear standard
curve.
Phenotype determination. The acetylation pheno-
type of 20 individuals, previously tested with dap-
sone, was determined by use of the modified caffeine
method. Subjects chosen were slow (eight), interme-
diate (eight), or rapid (four) metabolizers of dapsone.
The dapsone method relies on determination of the ra-
tio of N-acetyldapsone to dapsone in serum, 3 hours
after oral administration of the parent drug.' A N-
acetyldapsone/dapsone ratio of 0.26 separates slow
from rapid acetylators.
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RESULTS
The separation of the methylurate and methylxan-
thine metabolites by use of the modified method is
illustrated in Fig. 2. Standard curves plotting integrated
signal values versus urinary metabolite concentrations
were linear for AAMU (up to 80 mg/L; r 0.998)
and for IX and 1U (up to 50 mg/L; r 0.996). In-
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Fig. 4. Distribution histograms of a random population group of 42 unrelated individuals, comparing
(AAMU)/(1X) with (AAMU)/(AAMU + 1U + IX) ratios. Antimodes at 1.82 and 6.60 for the
former ratio and 0.38 and 0.66 for the latter ratio separates slow acetylators and homozygous rapid
acetylators from heterozygous rapid acetylators. Inset figures indicate observed and expected gen-
otypic values by application of the Hardy-Weinberg theory. The slow gene (q) frequency (S/total
number)1/2 was equal to 0.69.
terday coefficients of variation were as follows: 6% to
12% for AAMU, 4% to 12% for 1X, and 5% to 11%
for 1U.
The N-acetyldapsone/dapsone ratio is compared
with the urinary molar ratio of (AAMU)/(AAMU +
1U + 1X) and (AAMU)/ (1X) (Fig. 3). Arbitrary an-
timodes at 1.82 and 6.60 for the (AAMU)/ (1X) ratio,
0 0 0.2 0.4 0.6 0.8 1.0 O 4 6 8 10
[AAMU]/[AAMU + 1U + 1X1 [AAMU]/[1X]
Fig. 3. Twenty individuals of known acetylator phenotype were tested with the modified caffeine
method. The urinary molar ratios of (AAMU)/(AAMU + 1U + IX) and (AAMU)/(1X) are
plotted against the N-acetyldapsone/dapsone (MADDS/DDS) ratio. Subjects A and B were dis-
cordant when the (AAMU)/(AAMU + 1U + IX) ratio was used because of concurrent admin-
istration of theophylline.
0.0 0.0
Table I. Metabolic profiles of subjects and family pedigrees
and 0.38 and 0.66 for the (AAMU)/ (AAMU +
1U + 1X) ratio, separate slow, intermediate and
rapid acetylators. There was close phenotypic corre-
lation between the N-acetyldapsone/dapsone ratio and
the urinary molar ratio of (AAMU)/ (1X), but the
(AAMU)/(AAMU + 1U + 1X) ratio for two individ-
uals (A and B) was distorted. A more comprehensive
analysis of the trimodal acetylation patterns, observed
by use of the modified caffeine method, was subse-
Urinary metabo ite concen rations (mol/L), (AAMU)/(AAMU + 1U + IX), and (AAMU)/(1X) molar ratios and family pedigrees. For acetylation genotype
determination in the family pedigrees, the molar ratio of (AAMU)/(1X) was used.
AAMU, 5-Acetylamino-6-amino-3-methyuracil; 1U, 1-methyluric acid; IX, 1-methylxanthine.
*Subjects A and B.
quently undertaken by testing 42 unrelated healthy sub-
jects. The trimodal distribution patterns of acetylation
in this group is demonstrated by the histogram (Fig.
4), in which the observed values are consistent with
those expected by application of the Hardy-Weinberg
theory of population genetics.
Studies of informative families were also under-
taken to further evaluate the potential genotyping
capacity of this method. The urinary concentra-
Subject
No.
[AAMUI
moles/L
[1 Ul
moles/L
11X1
moles/L
likardaly
FAA,Au.
.1 U.1 Xj
[AAMLIF
DM
Fam ily Pedigrees
42 0.015 0.060 0.026 G.15 0.57
43 0.140 0.085 0.144 0.37 0.97 1 o
44 0.200 0.160 0.100 0.43 2.00 li 6
45 0.500 0.200 0.160 0.58 3.12
46 0.091 0.278 0.070 0.21 1.30
47 0.240 0.401 0.160 0.30 1.50 1E1
48 0.090 0.230 0.130 0.20 0.69
49 0.053 0.144 0.110 0.21 0.88
50 0.015 0.030 0.025 0.21 0.60
51
52
0.190
0.130
0.430
0.200
0.200
0.130
0.23
0.28
0.95
1.00
11-1-41:i
53 0.180 0.280 0.110 0.31 1.00
54 0.090 0.090 0.070
0.050
0.36
0.18
1.28
0.8055
56
57
0.040
0.090
0.250
0.130
0.126
0.256
0.052
0.160
0.34
0.37
1.73
1.56
58 0.150 0.190 0.124 0.33 1.20
59 0.170
0.320
0.120
0.230
0.080
0.100
0.46
0.49
2.12
3.2060
61
62
0.720
0.050
0.600
0.160
0.270
0.100
0.45
0.16
2.60
0.50
63 0.700 0.420 0.160 0.55 4.37
64 0.060 0.160 0.180 0.15 0.33
65 0.180 0.310 0.120 0.30 1.50 11E11
66 0.600 1.200 0.550 0.25 1.10
67 0.230 0.670 0.440 0.17 0.52
68 0.300 0.370 0.070 0.40 4.20
69 0.090 0.040 0.030 0.56 3.00 11[)}-11
70 0.020 0.400 0.020 0.05 1.00
71 0.300 0.230 0.130 0.45 2.30
72 0.420 0.200 0.130 0.56 3.20
73
74
0.090
0.125
0.090
0.060
0.070
0.040
0.36
0.55
1.00
3.12
111-T-11141
75 0.123 0.070 0.050 0.50 2.46
Subject
No.
[AANILI1
moles/L
Il IA
moles/L
[1X1
moles/L
[AAMUF
[AAMUs
i uo xi L^"""I'[1X1 Family Pedigrees
1 0.080 0.250 0.090 0.19 0.90
2 0.220 0.260 0.200 0.33 1.10
3 0.500 0.700 0.550 0.30 0.90 1
4 0.280 0.400 0.320 0.28 0.87 ii ii 4 ii
5 0.250 0.230 0.170 0.37 1.50
6 0.020 0.040 0.030 0.20 0.66
7 0.134 0.028 0.020 0.74 6.70
8 0.080 0.022 0.010 0.71 8.00 r(2):5
9 0.052 0.106 0.007 0.32 * 7.43
10 0.055 0.103 0.008 0.33 * 6.88
11 0.044 0.037 0.012 0.47 3.66
12 0.036 0.040 0.017 0.39 2.12
13 0.096 0.106 0.105 0.31 0.91
14 0.100 0.062 0.030 0.52 3.26
15 0.260 0.147 0.080 0.53 3.32
16 0.220 0.250 0.160 0.33 1.34
17
18
0.060
0.072
0.030
0.062
0.029
0.030
0.50
0.44
2.07
2.40
19
20
0.153
0.372
0.101
0.210
0.070
0.107
0.48
0.54
2.28
3.47 F
21 0.150 0.085 0.080 0.47 1.90
22 0.150 0.048 0.030 0.65 5.00
23 0.527 0.181 0.072 0.68 7.32
24 0.187 0.056 0.022 0.71 8.50
25 0.092 0.053 0.028 0.53 3.28 ii
26 0.030 0.025 0.006 0.49 5.00 111149. ;Pro
27 0.080 0.048 0.016 0.55 5.00
28 0.084 0.060 0.026 0.49 3.23
29 0.142 0.033 0.017 0.74 8.35
30 0.377 0.086 0.042 0.75 8.97
31 0202 0.094 0.053 0.58 3.81
32 0.202 0.138 0.097 0.46 2.08
111--)1-1
33 0.020 0.017 0.004 0.49 5.00
34 0.014 0.028 0.019 0.23 0.74
35
36
0.068
0.118
0.078
0.145
0.066
0.116
0.32
0.31
1.03
1.01
lir ill:
37 0.180 0.386 0.252 0.22 0.82
38 0.172 0.220 0.160 0.31 1.07
39 0.160 0.230 0.200 0.27 0.80 I l
40
41
0.600
0.031
0.800
0.170
0.170
0.020
0.39
0.14
3.50
1.50
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= Homozygous Slow Acetylator
111= Heterozygous Rapid Acetylator
0. Male 10 = Female 0. Homozygous Rapid Acetylator
Table II. Observed matings from 16 marriages and resulting genotypes of offspring compared with
expected values
Genotype No. of No. of
matings marriages children
rr X rr 6 15
Rr x Rr 2 7
Rr x rr 5 11
RR x Rr 2 8
RR x RR 1 2
RR x rr
o
o
o
2
2
RR Rr
tion of relevant caffeine metabolites, individual
(AAMU)/(AAMU + 1U + 1X) and (AAMU)/ (1X)
ratios and family pedigree analysis are outlined in Table
I. The observed genotypic matings and resulting off-
spring in 16 white families (75 individuals) are com-
pared with those expected (Table II). The x2 calcu-
lations reflect no significant difference between the
observed values and those expected by classical Men-
delian segregation.
DISCUSSION
When isonicotinic acid hydrazide (isoniazid) was first
introduced as a tuberculostatic chemotherapeutic agent
in the early 1950s,22 it soon became apparent that
considerable interindividual variation in the urinary
excretion rates of the parent compound and its acety-
lated metabolite existed.23-25 This variation in isonia-
zid acetylation was later shown to be genetically
determinee" and reflected varying activity of human
liver N-acetyltransferase.3 Peripheral neuritis was ob-
served in slow metabolizers of isoniazid,"'" and since
then, several important associations between acetylator
status and clinical disorders have been described.
Drug toxicities of significance include the develop-
ment of lupus erythematosus in slow metabolizers ex-
posed to hydralazine" and procainamide."'" Slow acet-
ylators exposed to sulfasalazine exhibit cutaneous
discoloration' and hematologic abnormalities,' which
are attributed to high levels of the sulfa metabolite, N-
hydroxysulfapyridine."'" Statistical associations exist
between slow acetylator phenotype and the develop-
ment of bladder cancer."' A significant association
also exists between the rapid acetylator phenotype and
type I (insulin-dependent) diabetes mellitus in Euro-
peans."'39
To further evaluate the potential implications of the
acetylation polymorphism and its effect on human re-
sponse to drugs, especially in well-documented clinical
situations, a rapid, noninvasive, and easily reproducible
rr
o o
o
1.75
o
4
2
RR, Homozygous rapid acetylator; Rr, heterozygous rapid acetylator; rr, slow acetylator; NS, not significant.
Expected
Rapid Slow
RR Rr
o 15
3.50 1.75
5.5 5.5
4
rr A; Values
2.42 (NS)
2.28 (NS)
2.00 (NS)
genotyping method would be desirable. In elucidation
of the efficacy of the modified caffeine genotyping
method, several problems were encountered that war-
rant amplification. Because of instability of AFMU,
notably at pH 5 or greater,' and its degradation over
time," we proceeded to deformylate AFMU to the sta-
ble compound,' AAMU, knowing this conversion
had, in all probability, partially occurred in urine pres-
ent in the bladder under physiologic pH conditions.'
Furthermore, because of incomplete resolution of
AFMU by use of the single C,, reverse-phase column,
we elected to phenotype individuals by use of the
(AAMU)/(AAMU + 1U + 1X) ratio, as described
by Tang et al.' It became apparent, however, that in-
complete separations of 1U from 7X frequently oc-
curred. This particular problem has been observed in
other HPLC systems when attempting to separate 7-
methylxanthine and 1-methyluric acid.' The addition
of a phenyl column in advance of and in tandem with
the C18 column resulted in satisfactory resolution of the
1U and 7X metabolites. The phenyl column was se-
lected for the separation of these metabolites on the
basis of previous success with this column for the sep-
aration of methylated purines."
Two of our test subjects (A and B, Fig. 3) were
receiving theophylline for bronchial asthma. Our
observations suggested that, when testing subjects
on theophylline, the acetylator genotype determina-
tion must be interpreted with caution when the
(AAMU)/ (AAMU + 1U + 1X) ratio is used. High
urinary 1-methyluric acid (and coincidental low 1-
methylxanthine) levels in subjects taking theophylline
have been described."'" An apparent slower acetylating
capacity of these individuals is thus reflected by the
(AAMU)/ (AAMU + 1U + 1X) molar ratio. Con-
sequently, the alternative ratio of (AAMU)/ (IX),
which showed excellent correlation with the N-
acetyldapsone / dapsone ratio (Fig. 3), could be used to
good effect in this situation.
VOLUME 47
NUMBER 4 N-Acetylation and caffeine metabolism 475
Observed
Rapid Slow
o 15
5 2
8 3
6 o
476 Kilbane et al.
The results of family pedigree analysis (Tables I and
II) are in keeping with Mendelian segregation patterns.
The genotypic findings are consistent throughout and
demonstrate trimodal distribution patterns of acetyla-
tion in this population group, as has been demonstrated
previously with the caffeine method by Tang et al.' As
several of the families studied included children with
type I diabetes mellitus, the effect of high blood glucose
on acetylator status might be questioned. Previous
studies" have shown no difference in acetylator status
in subjects tested over widely differing blood glucose
concentrations.
Problems with AFMU instability, particularly when
stored in the bladder, are avoided when deformylation
to AAMU is undertaken.' Our data suggest that the
ratio of (AAMU)/ (IX), based on family studies, reli-
ably separates the three genotypes and is suggested as
the ratio of choice for future investigation. It is also
clear that, in this situation, measurement of urinary 1-
methyluric acid is no longer warranted because it offers
no additional assistance when identification of the gen-
otypes is attempted. The addition of a phenyl column
(used in this study for accurate quantitation of 1U) will,
therefore, not be required when the urinary ratio of
(AAMU)/ (1X) is used to determine the acetylator gen-
otype. With each run for the size exclusion column
taking 35 to 40 minutes, up to 12 individuals could be
genotyped in a day.
Our study has reconfirmed the trimodal distribution
patterns of acetylation in a population group with use
of caffeine as a test drug, highlighted several problems
in methods that were rectified, extended previous ob-
servations to include detailed family studies that dem-
onstrate the expected Mendelian segregation patterns,
and shown that the (AAMU)/ (1X) ratio is preferable
to the (AAMU)/(AAMU + 1U + 1X) ratio in distin-
guishing heterozygous from homozygous rapid acety-
lators. The data also suggest the ratio (AAMU)/ (IX)
can be used reliably when estimating acetylation ca-
pacity in patients taking theophylline, but this warrants
further investigation.
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